Novartis AG researches develops manufactures and markets healthcare products worldwide The company operates through two segments Innovative Medicines and Sandoz The Innovative Medicines segment offers prescription medicines for patients and healthcare providers It also provides ophthalmology neuroscience immunology hepatology dermatology respiratory cardiovascular renal and metabolism medicine products The Sandoz segment develops manufactures and markets finished dosage form medicines active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties and retail generics and antiinfectives It also provides active pharmaceutical ingredients and intermediates primarily antibiotics protein or other biotechnologybased products including biosimilars and biotechnology manufacturing services Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop manufacture and commercialize inclisiran and a clinical collaboration with Kura Oncology Inc to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma The company was incorporated in 1996 and is headquartered in Basel Switzerland
0.00%
Last week
1 Week Post-Dividend Price Movement
Price Movement Trend 0.0% upward movements, 0.0% stable prices after dividend payments
Warning: include(/home/individends/public_html/dividend-content.php?ajax=true&ticker=NOVN.SW): Failed to open stream: No such file or directory in /home/individends/public_html/stock.php on line 708
Warning: include(): Failed opening '/home/individends/public_html/dividend-content.php?ajax=true&ticker=NOVN.SW' for inclusion (include_path='.:/opt/cpanel/ea-php83/root/usr/share/pear') in /home/individends/public_html/stock.php on line 708
Novartis AG (NOVN.SW) Profile
Novartis AG researches develops manufactures and markets healthcare products worldwide The company operates through two segments Innovative Medicines and Sandoz The Innovative Medicines segment offers prescription medicines for patients and healthcare providers It also provides ophthalmology neuroscience immunology hepatology dermatology respiratory cardiovascular renal and metabolism medicine products The Sandoz segment develops manufactures and markets finished dosage form medicines active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties and retail generics and antiinfectives It also provides active pharmaceutical ingredients and intermediates primarily antibiotics protein or other biotechnologybased products including biosimilars and biotechnology manufacturing services Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop manufacture and commercialize inclisiran and a clinical collaboration with Kura Oncology Inc to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma The company was incorporated in 1996 and is headquartered in Basel Switzerland